secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001140361-25-041225
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis reports Phase 3 olezarsen results: 72% TG reduction, 85% fewer pancreatitis events
--------------------------------------------------------------------------------

- Primary endpoint met: up to 72% placebo-adjusted mean reduction in fasting triglycerides at 6 months, sustained through 12 months (p<0.001).
- 85% reduction in acute pancreatitis events (p<0.001); 86% of patients achieved TG <500 mg/dL, below risk threshold.
- Favorable safety profile; serious AEs lower in olezarsen (9-11%) vs placebo (14%); most common AE mild injection site reactions.
- sNDA for 50 mg and 80 mg doses to be submitted to FDA by end of 2025; PDUFA target action date in 2026.
- Data presented at AHA Scientific Sessions and simultaneously published in The New England Journal of Medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036125041225/0001140361-25-041225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036125041225/ef20058520_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-041225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer